Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 4/20 | 0.60 |
| ▸ | MMP3 | P08254 | 2/20 | 0.60 |
| ▸ | MMP1 | P03956 | 13/20 | 0.58 |
| ▸ | MMP2 | P08253 | 4/20 | 0.58 |
| ▸ | MMP9 | P14780 | 4/20 | 0.58 |
| ▸ | MMP12 | P39900 | 4/20 | 0.58 |
| ▸ | MMP14 | P50281 | 4/20 | 0.58 |
| ▸ | MMP15 | P51511 | 4/20 | 0.58 |
| ▸ | MMP16 | P51512 | 4/20 | 0.58 |
| ▸ | MMP7 | P09237 | 3/20 | 0.58 |
| ▸ | MMP26 | Q9NRE1 | 3/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427221 | 0.90 | MMP1 (0.71) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427231 | 0.88 | THRB (0.52) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427229 | 0.88 | THRB (0.52) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL12955748 | 0.88 | THRB (0.52) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL5439958 | 0.85 | MMP8 (0.56) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL5160395 | 0.83 | MMP8 (0.60) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427227 | 0.81 | MMP1 (0.54) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427217 | 0.81 | MMP1 (0.54) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427251 | 0.78 | MMP1 (0.57) | MMP8MMP3MMP1MMP2MMP9 | |
| SCHEMBL14427181 | 0.78 | MMP8 (0.56) | MMP8MMP3MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | MMP8 18/4885MMP3 3/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.